Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 29 entities : Bristol-myers squibb company save search
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Published: 2021-06-29 (Crawled : 13:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.0%
H: 0.32%
C: -0.2%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.08%
H: 1.06%
C: 0.68%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: -2.19%
H: 17.95%
C: 16.17%
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: 33.33%
H: 0.0%
C: -20.52%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.81%
H: 0.0%
C: -5.95%
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: -0.59%
H: 0.17%
C: -17.64%
treatment glioblastoma
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
Published: 2021-06-29 (Crawled : 12:15) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.0%
H: 0.32%
C: -0.2%
satellite treatment rosa europe therapy cancer colorectal cancer approval nivolumab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.